ROS1 and non-small cell lung carcinoma: Repotrectinib was first approved based on the TRIDENT-1 trials in November 2023 for the initial treatment of ROS1-linked NSCLC or as a second-line treatment in patients who have previously received ROS1-targeted drugs [37] such as larotrectinib.